ReviewFrontiers in oncology2023
The multidisciplinary approach to eosinophilia.
Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS.International journal of chronic obstructive pulmonary disease · 2024Trial
- Eosinophilia in the Tropics: Should Empirical Anthelmintic Treatment Be Considered Standard Practice? A Prospective Cohort Study.Tropical medicine & international health : TM & IH · 2026Article
- Article
- Redefining Hematology Referral Thresholds for Eosinophilia.European journal of haematology · 2026Review
- Rapidly progressive squamous lung cancer with peripheral blood eosinophilia in a 25-year-old woman: A case report.Oncology letters · 2026Article
- The Clinical Burden of Hypereosinophilic Syndrome in a Large United States Cohort.The journal of allergy and clinical immunology. In practice · 2026Article
- Prediction model to identify patients with hypereosinophilic syndrome using real-world data.The journal of allergy and clinical immunology. Global · 2026Article
- Hypereosinophilia: clinical and therapeutic approach in 2025.Current opinion in allergy and clinical immunology · 2025Review
- Benralizumab in a Patient With Refractory Eosinophilic Endocarditis.Journal of medical cases · 2025Article
- Th2-High Severe Asthma with Hypereosinophilia in the Spectrum of Type 2 Inflammatory Diseases.International journal of molecular sciences · 2025Review
- A Scoping Review of Eosinophilic Pneumonia and Antidepressants: An Association Not to Be Overlooked.Diseases (Basel, Switzerland) · 2025Review
- Optimizing diagnostic and management pathways for patients with eosinophilia of unknown origin: a multidisciplinary protocol for urgent and non-urgent evaluation.Frontiers in medicine · 2025Article
- Primary care physicians play a crucial role in diagnosing and managing rare eosinophilic diseases: HES and EGPA.Frontiers in medicine · 2025Review
- A Critical Case of Chronic Eosinophilic Leukemia: Diagnostic Criteria and Response to Cytarabine.Case reports in oncological medicine · 2025Article
- Hepatic Angiosarcoma with eosinophilia: A Case Report and Literature Review.International journal of women's health · 2025Article
- Chronic rhinosinusitis with nasal polyps: Key considerations in the multidisciplinary team approach.Clinical and translational allergy · 2025Review
- From hypereosinophilia to hypereosinophilic syndrome: real-world application of a two-tailed approach for HES diagnosis.Frontiers in immunology · 2025Observational
- Associations between eosinophils and cancer risk in the UK Biobank.International journal of cancer · 2024Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic granulocytes are normally present in low numbers in the bloodstream. Patients with an increased number of eosinophilic granulocytes in the differential count (eosinophilia) are common and can pose a clinical challenge because conditions with eosinophilia occur in all medical specialties. The diagnostic approach must be guided by a thorough medical history, supported by specific tests to guide individualized treatment. Neoplastic (primary) eosinophilia is identified by one of several unique acquired genetic causes. In contrast, reactive (secondary) eosinophilia is associated with a cytokine stimulus in a specific disease, while idiopathic eosinophilia is a diagnosis by exclusion. Rational treatment is disease-directed in secondary cases and has paved the way for targeted treatment against the driver in primary eosinophilia, whereas idiopathic cases are treated as needed by principles in eosinophilia originating from clonal drivers. The vast majority of patients are diagnosed with secondary eosinophilia and are managed by the relevant specialty-e.g., rheumatology, allergy, dermatology, gastroenterology, pulmonary medicine, hematology, or infectious disease. The overlap in symptoms and the risk of irreversible organ involvement in eosinophilia, irrespective of the cause, warrants that patients without a diagnostic clarification or who do not respond to adequate treatment should be referred to a multidisciplinary function anchored in a hematology department for evaluation. This review presents the pathophysiology, manifestations, differential diagnosis, diagnostic workup, and management of (adult) patients with eosinophilia. The purpose is to place eosinophilia in a clinical context, and therefore justify and inspire the establishment of a multidisciplinary team of experts from diagnostic and clinical specialties at the regional level to support the second opinion. The target patient population requires highly specialized laboratory analysis and therapy and occasionally has severe eosinophil-induced organ dysfunction. An added value of a centralized, clinical function is to serve as a platform for education and research to further improve the management of patients with eosinophilia. Primary and idiopathic eosinophilia are key topics in the review, which also address current research and discusses outstanding issues in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.